Kanghong Pharmaceutical's Conbercept ophthalmic injection added to national medical insurance catalog

Chengdu Kanghong Pharmaceutical Group announced its Conbercept Ophthalmic Injection, branded "Langmu," has been officially included in China's National Medical Insurance Drug Catalog (2025) as a Class B drug. This follows an announcement from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security.

The drug is approved for four major indications: wet age-related macular degeneration (AMD) in patients aged 50 or older, diabetic macular edema (DME), choroidal neovascularization (CNV), and macular edema secondary to retinal vein occlusion (RVO). Specific conditions for use include a prescription from a Level 3 hospital ophthalmologist or Level 2 and above ophthalmology specialist hospital, baseline corrected visual acuity between 0.05-0.5 at the first prescription, and prior approval with evidence from angiography or OCT scans.

The new medical insurance catalog will be effective from January 1, 2026. The company noted that the impact on its current operating performance cannot be accurately estimated due to the time required for implementation across various regions and hospitals. Investors are advised to exercise caution.